FDA wants a REMS for extended-release Zyprexa
Executive Summary
FDA will not approve Eli Lilly's long-acting version of its antipsychotic Zyprexa (olanzapine) without a Risk Evaluation and Mitigation Strategy, the agency says in a complete response letter. The depot version of the drug, which would be indicated for acute and maintenance treatment of schizophrenia in adults, has recently been approved in the EU and New Zealand. Although developing the REMS will not require a clinical trial, FDA's decision is another delay for the product. The agency had previously rejected the line extension, which had been using the tradename Zyprexa Adhera,in February 2008, saying it needed more information on the post-injection delirium and sedation observed in a small percentage of patients. Zyprexa, Lilly's top seller, loses patent protection in 2011
You may also be interested in...
Lilly Provides Regulatory Update On Two Key Drugs: Zyprexa LAI, Byetta LAR
Firm responds to FDA’s “complete response” letter for the long-acting atypical antipsychotic and anticipates a six-month review.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.